Home > Research > Publications & Outputs > Umbilical vein oxytocin for the treatment of re...
View graph of relations

Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind randomised controlled trial

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind randomised controlled trial. / Weeks, Andrew; Alia, G; Vernon, G et al.
In: Lancet, Vol. 375, No. 9709, 09.01.2010, p. 141-147.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Weeks, A, Alia, G, Vernon, G, Namayanji, A, Gosakan, R, Majeed, T, Hart, A, Jalfri, H, Nardin, J, Carroll, G, Fairlie, F, Raashid, Y, Mirembe, F & Alfirevic, Z 2010, 'Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind randomised controlled trial', Lancet, vol. 375, no. 9709, pp. 141-147. https://doi.org/10.1016/S0140-6736(09)61752-9

APA

Weeks, A., Alia, G., Vernon, G., Namayanji, A., Gosakan, R., Majeed, T., Hart, A., Jalfri, H., Nardin, J., Carroll, G., Fairlie, F., Raashid, Y., Mirembe, F., & Alfirevic, Z. (2010). Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind randomised controlled trial. Lancet, 375(9709), 141-147. https://doi.org/10.1016/S0140-6736(09)61752-9

Vancouver

Weeks A, Alia G, Vernon G, Namayanji A, Gosakan R, Majeed T et al. Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind randomised controlled trial. Lancet. 2010 Jan 9;375(9709):141-147. doi: 10.1016/S0140-6736(09)61752-9

Author

Weeks, Andrew ; Alia, G ; Vernon, G et al. / Umbilical vein oxytocin for the treatment of retained placenta (Release Study) : a double-blind randomised controlled trial. In: Lancet. 2010 ; Vol. 375, No. 9709. pp. 141-147.

Bibtex

@article{a9873a606504415198264a35aeb24cf6,
title = "Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind randomised controlled trial",
abstract = "BackgroundRetained placenta is associated with post-partum haemorrhage. Meta-analysis has suggested that umbilical injection of oxytocin could increase placental expulsion without the need for a surgeon or anaesthetic. We assessed the effect of high-dose umbilical vein oxytocin as a treatment for retained placenta.MethodsIn this double-blind, placebo-controlled trial, haemodynamically stable women with a retained placenta for more than 30 min were recruited from 13 sites in the UK, Uganda, and Pakistan. 577 women were randomly assigned by a computer-generated randomisation list stratified by centre to 30 mL saline containing either 50 IU oxytocin (n=292) or 5 mL water (n=285), which was injected into the placenta through an umbilical vein catheter. All trial participants, study workers, and data handlers were masked to individual allocations. The primary outcome was the need for manual removal of the placenta. Analysis was by intention to treat. This study is registered, number ISRCTN 13204258.FindingsThe primary outcome was recorded for all participants. We detected no difference between the groups in the need for manual removal of placenta (oxytocin 179/292 [61·3%] vs placebo 177/285 [62·1%]; relative risk 0·98, 95% CI 0·87—1·12; p=0·84). The need for manual removal was higher in the UK (overall 250/361 [69%]) than in Uganda (90/190 [47%]) or Pakistan (16/26 [62%]). Adverse events did not differ between the two groups.InterpretationUmbilical oxytocin has no clinically significant effect on the need for manual removal for women with retained placenta.FundingWHO, WellBeing of Women, Pakistan Higher Education Commission.",
author = "Andrew Weeks and G Alia and G Vernon and A Namayanji and R Gosakan and T Majeed and Anna Hart and H Jalfri and J Nardin and G Carroll and F Fairlie and Y Raashid and F Mirembe and Z Alfirevic",
year = "2010",
month = jan,
day = "9",
doi = "10.1016/S0140-6736(09)61752-9",
language = "English",
volume = "375",
pages = "141--147",
journal = "Lancet",
issn = "1474-547X",
publisher = "Lancet Publishing Group",
number = "9709",

}

RIS

TY - JOUR

T1 - Umbilical vein oxytocin for the treatment of retained placenta (Release Study)

T2 - a double-blind randomised controlled trial

AU - Weeks, Andrew

AU - Alia, G

AU - Vernon, G

AU - Namayanji, A

AU - Gosakan, R

AU - Majeed, T

AU - Hart, Anna

AU - Jalfri, H

AU - Nardin, J

AU - Carroll, G

AU - Fairlie, F

AU - Raashid, Y

AU - Mirembe, F

AU - Alfirevic, Z

PY - 2010/1/9

Y1 - 2010/1/9

N2 - BackgroundRetained placenta is associated with post-partum haemorrhage. Meta-analysis has suggested that umbilical injection of oxytocin could increase placental expulsion without the need for a surgeon or anaesthetic. We assessed the effect of high-dose umbilical vein oxytocin as a treatment for retained placenta.MethodsIn this double-blind, placebo-controlled trial, haemodynamically stable women with a retained placenta for more than 30 min were recruited from 13 sites in the UK, Uganda, and Pakistan. 577 women were randomly assigned by a computer-generated randomisation list stratified by centre to 30 mL saline containing either 50 IU oxytocin (n=292) or 5 mL water (n=285), which was injected into the placenta through an umbilical vein catheter. All trial participants, study workers, and data handlers were masked to individual allocations. The primary outcome was the need for manual removal of the placenta. Analysis was by intention to treat. This study is registered, number ISRCTN 13204258.FindingsThe primary outcome was recorded for all participants. We detected no difference between the groups in the need for manual removal of placenta (oxytocin 179/292 [61·3%] vs placebo 177/285 [62·1%]; relative risk 0·98, 95% CI 0·87—1·12; p=0·84). The need for manual removal was higher in the UK (overall 250/361 [69%]) than in Uganda (90/190 [47%]) or Pakistan (16/26 [62%]). Adverse events did not differ between the two groups.InterpretationUmbilical oxytocin has no clinically significant effect on the need for manual removal for women with retained placenta.FundingWHO, WellBeing of Women, Pakistan Higher Education Commission.

AB - BackgroundRetained placenta is associated with post-partum haemorrhage. Meta-analysis has suggested that umbilical injection of oxytocin could increase placental expulsion without the need for a surgeon or anaesthetic. We assessed the effect of high-dose umbilical vein oxytocin as a treatment for retained placenta.MethodsIn this double-blind, placebo-controlled trial, haemodynamically stable women with a retained placenta for more than 30 min were recruited from 13 sites in the UK, Uganda, and Pakistan. 577 women were randomly assigned by a computer-generated randomisation list stratified by centre to 30 mL saline containing either 50 IU oxytocin (n=292) or 5 mL water (n=285), which was injected into the placenta through an umbilical vein catheter. All trial participants, study workers, and data handlers were masked to individual allocations. The primary outcome was the need for manual removal of the placenta. Analysis was by intention to treat. This study is registered, number ISRCTN 13204258.FindingsThe primary outcome was recorded for all participants. We detected no difference between the groups in the need for manual removal of placenta (oxytocin 179/292 [61·3%] vs placebo 177/285 [62·1%]; relative risk 0·98, 95% CI 0·87—1·12; p=0·84). The need for manual removal was higher in the UK (overall 250/361 [69%]) than in Uganda (90/190 [47%]) or Pakistan (16/26 [62%]). Adverse events did not differ between the two groups.InterpretationUmbilical oxytocin has no clinically significant effect on the need for manual removal for women with retained placenta.FundingWHO, WellBeing of Women, Pakistan Higher Education Commission.

UR - http://www.scopus.com/inward/record.url?scp=73449147954&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)61752-9

DO - 10.1016/S0140-6736(09)61752-9

M3 - Journal article

AN - SCOPUS:73449147954

VL - 375

SP - 141

EP - 147

JO - Lancet

JF - Lancet

SN - 1474-547X

IS - 9709

ER -